Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05459688 · ClinicalTrials.gov registry record · Phase 2
Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124
A Phase 2 study of Hypertension, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 175
- Enrollment target
- 20
- Study locations
NCT05459688: Completed Phase 2 study of Hypertension, sponsored by AstraZeneca.
NCT05459688 is a Phase 2 study of Hypertension that has completed, run by AstraZeneca. The registered enrollment target is 175 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05459688, a Phase 2 study of Hypertension, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 175 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2, multicenter, open-label extension (OLE) study to evaluate the long-term safety, tolerability, and effectiveness of CIN-107 for up to 52 weeks in patients with HTN who have completed Part 1 or Part 2 of Study CIN-107-124. The study will be conducted at clinical sites that have participated in the double-blind, Phase 2 Study CIN-107-124.
Primary Outcome
An AE was defined as any untoward medical occurrence in a clinical investigation participants administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and/or unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an investigational medicinal product, whether or not related to the investigational medicinal product. Any medical condition al
Conditions Studied
Interventions
- DRUG CIN-107
Study Locations (20)
Florida
- Research Site - Clearwater
- Research Site - Doral
- Research Site - Hialeah
- Research Site - Hollywood
- Research Site - Lake Worth
- Research Site - Miami
- Research Site - Miami
- Research Site - Pembroke Pines
- Research Site - Winter Haven
California
- Research Site - Huntington Park
- Research Site - Lincoln
- Research Site - Los Angeles
- Research Site - Northridge
- Research Site - Oceanside
- Research Site - Panorama City
- Research Site - Van Nuys
Illinois
- Research Site - Addison
- Research Site - Chicago
- Research Site - Morton
Alabama
- Research Site - Saraland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2022-04-06 |
| Est. Completion | 2023-11-07 |
| Phase | Phase 2 |
What the finished NCT05459688 record still lists
NCT05459688 is an interventional study that assigns participants to a tested intervention. The registered 175 participants enrollment target is mid-sized for trials with a published cap, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which CIN-107 is the first listed.
NCT05459688 names 20 study sites across 4 states, led by Florida, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT05459688 about?
NCT05459688 is a clinical study titled "Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124". This is a Phase 2, multicenter, open-label extension (OLE) study to evaluate the long-term safety, tolerability, and effectiveness of CIN-107 for up to 52 weeks in patients with HTN who have completed Part 1 or Part 2 of Study CIN-107-124. The study will be conducted at clinical sites that have part...
What is the current status of trial NCT05459688?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 175 participants. The study started on 2022-04-06. Estimated completion is 2023-11-07.
What conditions does trial NCT05459688 study?
This clinical trial studies the following conditions: Hypertension.
What interventions are being tested in trial NCT05459688?
The interventions under investigation include: CIN-107 (DRUG).
Who is sponsoring clinical trial NCT05459688?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05459688 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05459688's enrollment target sits among peer trials
175 234th of 470 higher than 236 of 470 other Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults
RECRUITING · Phase 2
-
A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients
RECRUITING · Phase 2
-
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
RECRUITING · Phase 2
-
Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)
RECRUITING · Phase 2
-
PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis
RECRUITING · Phase 2
-
Virtual Diabetes Group Visits Across Health Systems
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04722341 · 175 participants · NA
Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators
- NCT05094037 · 175 participants · NA
Orthotic Treatment of Diabetic Foot Ulcers
- NCT05165745 · 175 participants · NA
Stick2PrEP Cisgender Women and Trans Individuals
- NCT05312255 · 175 participants · NA
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI